Chapter 27
Radiation therapy for clinically localized prostate cancer
Michelle Echevarria,
Peter A. Johnstone,
Kosj Yamoah,
Michelle Echevarria
Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
Search for more papers by this authorPeter A. Johnstone
Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
Search for more papers by this authorKosj Yamoah
Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
Search for more papers by this authorMichelle Echevarria,
Peter A. Johnstone,
Kosj Yamoah,
Michelle Echevarria
Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
Search for more papers by this authorPeter A. Johnstone
Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
Search for more papers by this authorKosj Yamoah
Department of Radiation Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
Search for more papers by this authorBook Editor(s):Philipp Dahm,
Roger R. Dmochowski,
Philipp Dahm
Minneapolis VA Health Care System and Department of Urology, University of Minnesota, Minneapolis, Minnesota, MN, USA
Search for more papers by this authorRoger R. Dmochowski
Vanderbilt University, Medical Center, North Nashville, TN, USA
Search for more papers by this authorFirst published: 06 July 2018
Summary
This chapter presents available evidence on several aspects of radiation treatment for men with organ-confined prostate cancer. It addresses a series of focused clinical questions that are addressed in a systematic fashion, including a comprehensive literature search, a rating of the quality of evidence, and an assessment of ratio of benefit and harm of a given treatment option. The clinical questions are: In a patient with localized prostate cancer selecting definitive external beam radiation, what is the optimal dose regimen? and In a patient with localized prostate cancer, is there a benefit with proton beam radiation therapy over photon radiation? The remaining clinical questions are: In a patient with newly diagnosed localized, high-risk prostate cancer, is hormonal therapy indicated as an adjunct to definitive radiation therapy? and In a patient with positive surgical margins, extra-prostatic extension, and/or seminal vesicle involvement after radical prostatectomy, is there a benefit for adjuvant radiation therapy over salvage radiation therapy?
References
- Kuban, D.A. et al. (2008). Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70 (1): 67–74.
- Kuban, D.A. et al. (2011). Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int. J. Radiat. Oncol. Biol. Phys. 79 (5): 1310–1317.
- Zietman, A.L. et al. (2010). Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J. Clin. Oncol. 28 (7): 1106–1111.
- Dearnaley, D.P. et al. (2007). Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8 (6): 475–487.
- Dearnaley, D.P. et al. (2014). Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 15 (4): 464–473.
- Peeters, S.T. et al. (2006). Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol. 24 (13): 1990–1996.
- Al-Mamgani, A. et al. (2008). Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 72 (4): 980–988.
- Beckendorf, V. et al. (2011). 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 80 (4): 1056–1063.
-
Michalski, J. et al. (2012).Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int. J. Radiat. Oncol. Biol. Phys.
83 (3): e363–e370.
10.1016/j.ijrobp.2011.12.070 Google Scholar
- Michalski, J.M. et al. (2010). Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int. J. Radiat. Oncol. Biol. Phys. 76 (1): 14–22.
- Kupelian, P.A. et al. (2007). Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int. J. Radiat. Oncol. Biol. Phys. 68 (5): 1424–1430.
- King, C.R. et al. (2013). Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother. Oncol. 109 (2): 217–221.
- Zietman, A.L. et al. (2005). Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (10): 1233–1239.
- Hoskin, P.J. et al. (2012). Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother. Oncol. 103 (2): 217–222.
- Morris, W.J. et al. (2015). ASCENDE-RT*: a multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J. Clin. Oncol. 33 (Suppl. 7): abstract 3.
- Vargas, C. et al. (2008). Dose–volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70 (3): 744–751.
- Michalski, J.M. et al. (2010). Radiation dose–volume effects in radiation-induced rectal injury. Int. J. Radiat. Oncol. Biol. Phys. 76 (3 Suppl.): S123–S129.
- Huang, E.H. et al. (2002). Late rectal toxicity: dose–volume effects of conformal radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 54 (5): 1314–1321.
- Yu, J.B. et al. (2013). Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J. Natl. Cancer Inst. 105 (1): 25–32.
- Coen, J.J. et al. (2012). Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 82 (2): e201–e209.
- Hoppe, B.S. et al. (2014). Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 120 (7): 1076–1082.
- Sheets, N.C. et al. (2012). Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307 (15): 1611–1620.
-
Kendal, W.S. et al. (2006). Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.
65 (3): 661–668.
10.1016/j.ijrobp.2005.11.013 Google Scholar
- Konski, A. et al. (2007). Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J. Clin. Oncol. 25 (24): 3603–3608.
- Roach, M., 3rd et al. (2008). Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26 (4): 585–591.
- Bolla, M. et al. (2010). External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11 (11): 1066–1073.
- Jones, C.U. et al. (2011). Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 365 (2): 107–118.
- Denham, J.W. et al. (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 12 (5): 451–459.
- Crook, J. et al. (2009). Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 73 (2): 327–333.
- Horwitz, E.M. et al. (2008). Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26 (15): 2497–2504.
- Bolla, M. et al. (2009). Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360 (24): 2516–2527.
- Zapatero, A. et al. (2015). High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 16 (3): 320–327.
-
Zietman, A.L. and Shipley, W.U. (1997). Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int. J. Radiat. Oncol. Biol. Phys.
37 (2): 245–246.
10.1016/S0360-3016(97)00122-3 Google Scholar
- Karakiewicz, P.I. et al. (2005). Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 66 (6): 1245–1250.
- Swindle, P. et al. (2005). Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol. 174 (3): 903–907.
- Bolla, M. et al. (2012). Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380 (9858): 2018–2027.
- Thompson, I.M. et al. (2009). Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181 (3): 956–962.
- Wiegel, T. et al. (2009). Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27 (18): 2924–2930.
- Wiegel, T. et al. (2014). Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur. Urol. 66 (2): 243–250.
- Stephenson, A.J. et al. (2007). Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 25 (15): 2035–2041.
- Trock, B.J. et al. (2008). Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (23): 2760–2769.
- Cotter, S.E. et al. (2011). Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 117 (17): 3925–3932.
- Den, R.B. et al. (2015). Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J. Clin. Oncol. 33 (8): 944–951.
